ALC vs MDGL
Alcon Inc vs Madrigal Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
MDGL
Madrigal Pharmaceuticals, Inc.
56
Watch
| Metric | ALC | MDGL |
|---|
| AI Score |
68
|
56
|
| Price |
$75.39
|
$535.01
|
| P/E Ratio |
45.39×
|
-41.53×
|
| ROE |
4.4%
|
-47.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
91.5%
|
| Debt / Equity |
0.24×
|
0.66×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
60.0
|
| Beta |
0.703
|
-1.003
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus MDGL.
ALC leads by 12 points.
ALC scores 68/100 (Buy) versus MDGL at 56/100 (Watch).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MDGL Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 149.0% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 21.9x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 149.0% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 21.9x prices in significant intangible value — Value
- ROE of only -56.6% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical